Biotechnology
MagicTouch SCB receives IDE approval for In-Stent Restenosis indication
TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ -- The US FDA has granted an
Investigational Device Exemption (IDE) approval forMagicTouch
Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA
SHANGHAI and BUCKS COUNTY, Pa., Sept. 20, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines ...
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®
SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at theUnivers...
New treatment for rare cancer cholangiocarcinoma approved in Australia
* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...
Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection
HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection has completed ...
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...
Austar Lifesciences Announces 2022 Interim Results
Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions,its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million Operation Highlights (RMB'000) For the six months ended 30 June ...
Food Pioneers Sophie's Bionutrients And NewFish Join Forces To Develop Dairy Alternatives From Microalgae
AMSTERDAM and AUCKLAND, New Zealand, Sept. 15, 2022 /PRNewswire/ -- Sophie's Bionutrients and NewFish®, two pioneers in the field of microalgae protein fermentation, with the support ofNew Zealand-based marine research powerhouse, Cawthron Institute, andNetherlands-based leading food university, ...
GenScript Receives Best Cell & Gene Therapy Supplier Award: Gene Editing and GenScript ProBio Receives Best Biologics CMO Awards: Upstream Processing & Analytical Services
SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) and GenScriptProBio (a global one-stop CDMO from GenScript Group) receive 3 awards: Best Cell & Gene Therapy Supplier Award – Gene Editing on the Asia-Pacific Cell & Gene Therapy Excellence ...
ClavystBio launches to translate life sciences breakthroughs into health impact
* ClavystBio will invest and work with partners to accelerate life sciences commercialisation inSingapore through three pillars: collaborate, venture and build. * ClavystBio has committed US$220 million to date in investments to launch global life sciences companies fromSingapore. SINGAPORE, ...
Juniper Biologics Establishes Global Headquarters in Singapore
Juniper Biologics' investment will support the growth and innovation of Singapore's pharmaceutical sector SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its ...
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft
tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the
appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr
as a Non-Executive Director to the board.
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD
Anderson Cancer Center
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s,among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS wa...
GBB Lands USD 15M Pre-Series B Funding Led by Tiger Jade Capital
HONG KONG, Sept. 13, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of itsUSD 15M Pre-series B funding led by Tiger Jade Capital (hereinafter referred to as "Tiger Jade"). The funding was oversubscribed and upsized with participat...
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022
* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line(1L)treatment for advanced NSCLC patients * In 87 efficacy evaluable patients, confirmed ORR was 46%. * Median OS in non-squ...
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)
* As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastatic GC/GEJ, with no prior systemic treatment, were enrolled. 27 patients were evaluable for efficacy. The ORR was 77.8% and DCR was 92.6%. * The phase III pivotal study is planned to confirm the eff...
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence
SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...
Week's Top Stories
Most Reposted
"Sanya-style Chinese New Year" becomes top trendsetter for the Spring Festival in China
[Picked up by 298 media titles]
2024-03-21 12:14iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00